Cat Vaccine Market Report 2025

This cat vaccine market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The cat vaccine market size has grown strongly in recent years. It will grow from $1.15 billion in 2024 to $1.26 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to rising emergence of new diseases in cats, increasing prevalence of animal diseases, increasing livestock population of animals, increasing population of companion animals, and increasing zoonotic diseases.

The cat vaccine market size is expected to see strong growth in the next few years. It will grow to $1.78 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to the rising trend of pet ownership, increasing disposable income, increasing demand for veterinary services, government and veterinary organization initiatives, and growing awareness of animal health among people. Major trends in the forecast period include development of advanced cat vaccines, innovative and more effective products, novel vaccine technologies, innovations in combination vaccines, and the development of personalized vaccinations.

The rise in zoonotic diseases is expected to drive the growth of the cat vaccine market. Zoonotic diseases are infections that can transfer from animals to humans through various pathogens such as bacteria, viruses, fungi, or parasites. These diseases can be transmitted via direct contact, vectors, or contaminated environments. Common zoonotic diseases include Lyme disease, rabies, toxoplasmosis, salmonellosis, and brucellosis. Factors contributing to the increase in zoonotic diseases include climate change, antibiotic resistance, and wildlife trade. Cat vaccines help manage these diseases by reducing the risk of transmission from cats to humans. For instance, they protect against diseases such as toxoplasmosis and cat scratch fever. By vaccinating cats, the impact of zoonotic diseases on human health is mitigated, supporting public health and creating a healthier environment for both pets and their owners. According to a February 2024 report from the Government of the United Kingdom, England saw 335 confirmed cases of Lyme disease in the fourth quarter of 2023, up from 273 cases in the same period in 2022. This increase underscores the growing demand for cat vaccines driven by rising zoonotic diseases.

Key players in the cat vaccine market are innovating with products such as NOBIVAC NXT vaccines, which use advanced Ribonucleic acid (RNA)-particle technology to boost immune responses and enhance vaccine effectiveness. This technology involves RNA molecules encased in nanoparticles that deliver genetic instructions to cells, prompting them to produce specific proteins that trigger a targeted immune response. For example, in June 2024, MSD Animal Health Inc. launched the NOBIVAC NXT Rabies portfolio, including NOBIVAC NXT Feline-3 Rabies and NOBIVAC NXT Canine-3 Rabies. These vaccines offer robust protection against rabies for cats and dogs without adjuvants or preservatives, improving safety while maintaining efficacy. They stimulate both humoral and cell-mediated immune responses for comprehensive protection against the rabies virus.

In September 2024, Boehringer Ingelheim Group, based in Germany, acquired Saiba Animal Health AG, a Switzerland-based company specializing in cat vaccines. This acquisition aligns with Boehringer Ingelheim's strategy to expand its portfolio and leverage Saiba’s expertise in the field.

Major companies operating in the cat vaccine market are Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., MSD Animal Health, Elanco Animal Health Incorporated, Intas Pharmaceuticals Ltd., Ceva Santé Animale, Virbac, Neogen Corporation, Indian Immunologicals Ltd., Jinyu Bio-technology Co. Ltd., Ourofino Animal Health SA, Biogénesis Bagó SA, Valley Vet Supply, HIPRA Corporation, Bioveta AS, China Animal Husbandry Group, Veterinary Pharmaceutical Solutions, Torigen Pharmaceuticals Inc., KM Vet Pharm Sdn Bhd.

North America was the largest region in the cat vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cat vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cat vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A cat vaccine is a biological agent designed to safeguard cats from infectious diseases by activating their immune system to identify and combat specific pathogens. These vaccines use weakened or inactivated versions of viruses or bacteria responsible for diseases, which prompts the cat’s immune system to generate antibodies without causing illness.

Ther main categories of cat vaccines are modified or attenuated live vaccines, inactivated vaccines, and others. Modified or attenuated live vaccines involve weakening the pathogen to prevent it from causing illness in cats. These vaccines address various diseases such as feline leukemia, feline panleukopenia, feline respiratory infections, and feline rabies. The available vaccine technologies include attenuated live vaccines, conjugate vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, and recombinant vaccines. They can be administered through different methods, including injections, intranasal, and oral routes. These vaccines are available through various channels, including veterinary clinics, pet stores, and online retailers.

The cat vaccine market research report is one of a series of new reports that provides cat vaccine market statistics, including cat vaccine industry global market size, regional shares, competitors with a cat vaccine market share, detailed cat vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the cat vaccine industry. This cat vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cat vaccine market consists of sales of the bordetella vaccine, rabies vaccine, and feline immunodeficiency virus (FIV) vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.